Epoxy adhesive Duplomix DM10 - new - NC - B

Hazard statements (CLP)

H315, H317, H319, H412

Code

Statements

H315

Causes skin irritation

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification according to directive (EC) No

Health hazards

Skin irritation, Category 2 H315: Causes skin irritation. Eye irritation, Category 2 H319: Causes severe eye irritation. Skin sensitisation, Category 1 H317: May cause an allergic skin reaction. (Chronic) Aquatic long-term hazard, Category 3 H412: Harmful to aquatic life with long lasting effects.

2.2 Label elements

Labelling

Signal word

Warning. Hazardous ingredients to be declared on the label: • Poly[oxy(methyl-1,2-ethanediyl)], α-hydro-ω-hydroxy, ether with 2,2-bis(hydroxymethyl)-1,3- propanediol (4:1), 2-hydroxy-3-mercaptopropyl ether • N´-(3-Aminopropyl)-N,N-dimethylpropane-1,3-diamine

Hazard statements

H315 Causes skin irritation. H317 May cause an allergic skin reaction. H319 Causes severe eye irritation. H412 Harmful to aquatic life with long-lasting effects.

Prevention

P261 Avoid inhalation of dust/fume/gas/mist/vapour/spray. P264 After handling this product, wash skin thoroughly. P273 Avoid discharge into the environment. P280 Wear protective gloves/eye protection/face protection. Action: P333 + P313 In case of skin irritation or rash: consult a doctor. P337 + P313 In case of persistent eye irritation: consult a doctor.

2.3 Other hazards

This substance/mixture does not contain any components that can be considered persistent, bioaccumulative and toxic (PBT) or as very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

ECOLOGICAL INFORMATION

The substance/mixture does not contain any components whose assumed to have endocrine-disrupting properties, according to REACH article 57(f) or the Commission's delegated regulation (EU) 2017/2100 or the regulation of the Commission (EU) 2018/605 at level 0.1% or above.

TOXICOLOGICAL INFORMATION

The substance/mixture does not contain any components whose assumed to have endocrine-disrupting properties, according to REACH article 57(f) or the Commission's delegated regulation (EU) 2017/2100 or the regulation of the Commission (EU) 2018/605 at level 0.1% or above.